The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood and Marrow Transplantation (EBMT) the number of MF has increased from 515 in 2014 to 748 in 2018 . This reflects the fact that HSCT is currently the only curative treatment, capable of inducing prolonged disease-free survival. Nevertheless, several problems prevent more patients from undergoing an allogeneic HSCT: we will be discussing indications for HSCT, comorbidities, splenomegaly, older age and disease phase. Donor type and stem cell source are less of a problem. Several transplant platforms exist, including different strategies for graft versus host disease (GvHD) prophylaxis, Age tailored conditioning regimens need to be implemented, to allow older and fragile patients to undergo an allogeneic HSCT.

中文翻译：

---

2021 年异基因造血干细胞移植治疗骨髓纤维化的更新：对当前风险分层和管理数据和应用的回顾

接受同种异体造血干细胞移植 (HSCT) 的骨髓纤维化 (MF) 患者数量正在增加：在欧洲血液和骨髓移植组织 (EBMT) 的分析中，MF 的数量从 2014 年的 515 人增加到 2014 年的 748 人2018 年。这反映了一个事实，即 HSCT 是目前唯一的治疗方法，能够诱导延长无病生存期。然而，一些问题阻碍了更多患者接受异基因 HSCT：我们将讨论 HSCT 的适应症、合并症、脾肿大、年龄较大和疾病阶段。供体类型和干细胞来源问题不大。存在多种移植平台，包括移植物抗宿主病 (GvHD) 预防的不同策略，需要实施针对年龄的预处理方案，